Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: An open, multicentre, retrospective study

British Journal of Dermatology

Volumn 165, Issue 6, 2011, Pages 1337-1343

  Du Thanh, A ^a   Merlet, S ^a   Maillard, H ^b   Bernard, P ^c   Joly, P ^d   Esteve E ^e   Richard, M A ^f   Pauwels, C ^g   Ingen Housz Oro, S ^h   Guillot, B ^a   Dereure, O ^a  

^a UNIV MONTPELLIER   (France)

^b CENTRE HOSPITALIER DU MANS   (France)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e Hospital of Orleans   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; CLOBETASOL PROPIONATE; FOLIC ACID; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BULLOUS PEMPHIGOID; DEPRESSION; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE ULCER; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELENA; MOUTH ULCER; OPEN STUDY; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PEMPHIGOID, BULLOUS; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 82255194113     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10531.x     Document Type: Article

References (27)

1. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691-8. (Pubitemid 41001068)
2. Langan SM, Hubbard R, Fleming K, West J,. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol 2009; 161: 1149-52.
3. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-9. (Pubitemid 28207630)
4. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138: 903-8. (Pubitemid 34700736)
5. Berk MA, Lorincz AL,. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986; 122: 670-4. (Pubitemid 16115845)
6. Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34: 683-4. (Pubitemid 26098022)
7. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53. (Pubitemid 23029669)
8. Itoh T, Hosokawa H, Shirai Y, Horio T,. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996; 134: 931-3. (Pubitemid 26150293)
9. Barthelemy H, Thivolet J, Cambazard F, et al. La ciclosporine dans le traitement de la pemphigoide bulleuse: étude préliminaire. Ann Dermatol Venereol 1986; 113: 309-13. (Pubitemid 16096731)
10. Chave TA, Mortimer NJ, Shah DS, Hutchinson PE,. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004; 151: 1107-8. (Pubitemid 39573909)
11. Grundmann-Kollmann M, Kaskel P, Leiter U, et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999; 135: 724-5. (Pubitemid 29277853)
12. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40: 957-60. (Pubitemid 29268927)
13. Nousari HC, Anhalt GJ,. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol 2000; 136: 1204-5.
14. Korman NJ,. New immunomodulating drugs in autoimmune blistering diseases. Dermatol Clin 2001; 19: 637-48, viii. (Pubitemid 33041644)
15. Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741-9. (Pubitemid 29230362)
16. Paul MA, Jorizzo JL, Fleischer AB Jr, White WL,. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994; 31: 620-5. (Pubitemid 24309781)
17. Gurcan HM, Ahmed AR,. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161: 723-31.
18. Kjellman P, Eriksson H, Berg P,. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008; 144: 612-16. (Pubitemid 351724421)
19. Chu J, Bradley M, Marinkovich MP,. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003; 139: 813-15. (Pubitemid 36705959)
20. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129: 1681-7.
21. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7. (Pubitemid 34438839)
22. Bara C, Maillard H, Briand N, Celerier P,. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139: 1506-7. (Pubitemid 37433147)
23. Dereure O, Bessis D, Guillot B, Guilhou JJ,. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002; 138: 1255-6. (Pubitemid 35025711)
24. Vaillant L, Bernard P, Joly P, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 1998; 134: 1075-80. (Pubitemid 28432319)
25. National Cancer Institute. Common Terminology Criteria for Adverse Events, Version 4.03. Bethesda, MD: U.S. Department of Health and Human Services, National Institute of Health, National Cancer Institute, 2010.
26. Dreno B, Sassolas B, Lacour P, et al. [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]. Ann Dermatol Venereol 1993; 120: 518-21. (Pubitemid 23311842)
27. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; ii: 486-8.